Skip to main content
NASDAQ:SGMO

Sangamo Therapeutics News Headlines

$11.03
+0.14 (+1.29 %)
(As of 05/18/2021 09:44 AM ET)
Add
Compare
Today's Range
$10.94
$11.04
50-Day Range
$10.17
$12.64
52-Week Range
$8.51
$19.43
Volume1,608 shs
Average Volume1.39 million shs
Market Capitalization$1.59 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.97

Headlines

Sangamo Therapeutics (NASDAQ SGMO) News Headlines Today

SourceHeadline
Sangamo Therapeutics (NASDAQ:SGMO) Upgraded at Zacks Investment ResearchSangamo Therapeutics (NASDAQ:SGMO) Upgraded at Zacks Investment Research
marketbeat.com - April 23 at 3:30 AM
Wasatch Global on Sangamo (SGMO): “We Remain Optimistic About its Future Prospects”Wasatch Global on Sangamo (SGMO): “We Remain Optimistic About its Future Prospects”
finance.yahoo.com - May 12 at 6:57 PM
Sangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Coverage Initiated by Analysts at Royal Bank of Canada
americanbankingnews.com - May 10 at 11:02 AM
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Analysts at Royal Bank of Canada
americanbankingnews.com - May 10 at 11:02 AM
Zacks: Brokerages Expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Will Post Earnings of -$0.27 Per ShareZacks: Brokerages Expect Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Will Post Earnings of -$0.27 Per Share
americanbankingnews.com - May 7 at 9:22 AM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 8:27 AM
Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 4.9% After Earnings MissSangamo Therapeutics (NASDAQ:SGMO) Stock Price Down 4.9% After Earnings Miss
americanbankingnews.com - May 5 at 12:37 PM
Sangamo Therapeutics (NASDAQ:SGMO) Releases  Earnings Results, Misses Estimates By $0.03 EPSSangamo Therapeutics (NASDAQ:SGMO) Releases Earnings Results, Misses Estimates By $0.03 EPS
americanbankingnews.com - May 4 at 11:46 PM
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial ResultsSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2021 Financial Results
markets.businessinsider.com - May 4 at 6:35 PM
Sangamo Therapeutics, Inc. 2021 Q1 - Results - Earnings Call PresentationSangamo Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 4 at 6:31 PM
Sangamo Therapeutics (NASDAQ:SGMO) Now Covered by Royal Bank of CanadaSangamo Therapeutics (NASDAQ:SGMO) Now Covered by Royal Bank of Canada
americanbankingnews.com - May 3 at 5:32 PM
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and WebcastSangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast
finance.yahoo.com - April 27 at 7:18 PM
Sangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell TherapySangamo Therapeutics Announces Presentations at 2021 Annual Meeting of the American Society of Gene & Cell Therapy
finance.yahoo.com - April 27 at 7:18 PM
Sangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare DiseaseSangamo Therapeutics Announces Participation at Guggenheim Healthcare Talks: 2021 Genomic Medicines & Rare Disease
finance.yahoo.com - March 25 at 10:37 AM
Sangamo Therapeutics Shares Cross Below 200 DMASangamo Therapeutics Shares Cross Below 200 DMA
nasdaq.com - March 24 at 8:05 PM
What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?What’s Next After The 15% Rally For Sangamo Therapeutics Stock Last Week?
forbes.com - March 23 at 2:02 PM
First Week of November 19th Options Trading For Sangamo Therapeutics (SGMO)First Week of November 19th Options Trading For Sangamo Therapeutics (SGMO)
nasdaq.com - March 19 at 2:28 PM
Sangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell DiseaseSangamo Announces EMA Releases Details Supporting Orphan Designation for BIVV003 for the Treatment of Sickle Cell Disease
finance.yahoo.com - March 17 at 6:11 PM
What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.s (NASDAQ:SGMO) Share Registry?What Type Of Shareholders Make Up Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Registry?
finance.yahoo.com - March 9 at 2:10 PM
Revisting Sangamo TherapeuticsRevisting Sangamo Therapeutics
seekingalpha.com - March 8 at 10:19 PM
Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?Can Sangamo Therapeutics Stock Rebound After A 17% Drop Following Q4 Miss?
forbes.com - March 5 at 8:21 AM
Is Sangamo Therapeutics (SGMO) Stock a Buy For 2021?Is Sangamo Therapeutics (SGMO) Stock a Buy For 2021?
finance.yahoo.com - March 1 at 3:40 PM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 26 at 1:19 PM
Stock Market News for Feb 26, 2021Stock Market News for Feb 26, 2021
finance.yahoo.com - February 26 at 1:19 PM
Sangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call TranscriptSangamo Therapeutics Inc (SGMO) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 8:00 PM
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue EstimatesSangamo Therapeutics (SGMO) Reports Q4 Loss, Lags Revenue Estimates
nasdaq.com - February 24 at 11:59 PM
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial ResultsSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - February 24 at 6:58 PM
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and WebcastSangamo Therapeutics Announces Fourth Quarter and Full Year 2020 Conference Call and Webcast
finance.yahoo.com - February 17 at 8:07 PM
SGMO Mar 2021 17.000 callSGMO Mar 2021 17.000 call
uk.finance.yahoo.com - February 10 at 8:54 PM
SGMO Jan 2022 22.000 putSGMO Jan 2022 22.000 put
uk.finance.yahoo.com - February 10 at 8:54 PM
Sangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific OfficerSangamo Therapeutics Appoints Rob Schott, MD, MPH, FACC, as Head of Development; Elevates Jason Fontenot, PhD to Chief Scientific Officer
finance.yahoo.com - February 1 at 7:30 PM
SGMO Feb 2021 15.000 putSGMO Feb 2021 15.000 put
au.finance.yahoo.com - January 21 at 5:33 PM
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Years EstimatesSangamo Therapeutics, Inc. (NASDAQ:SGMO) Analysts Just Slashed Next Year's Estimates
finance.yahoo.com - January 8 at 8:27 AM
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung LeeSangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
finance.yahoo.com - January 6 at 4:23 PM
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceSangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 8:47 AM
Sangamo TherapeuticsSangamo Therapeutics
fool.com - December 25 at 11:21 PM
First Week of SGMO August 2021 Options TradingFirst Week of SGMO August 2021 Options Trading
nasdaq.com - December 18 at 2:22 PM
Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?Are Options Traders Betting on a Big Move in Sangamo Therapeutics (SGMO) Stock?
finance.yahoo.com - December 14 at 12:50 PM
SGMO Crosses Below Key Moving Average LevelSGMO Crosses Below Key Moving Average Level
nasdaq.com - December 7 at 4:36 PM
Pfizer, Sangamo Report Encouraging Findings From Phase 1/2 Study Of Giroctocogene FitelparvovecPfizer, Sangamo Report Encouraging Findings From Phase 1/2 Study Of Giroctocogene Fitelparvovec
nasdaq.com - December 7 at 11:35 AM
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene TherapyPfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels in 3x1013 VG/KG Cohort Through One Year Following Hemophilia A Gene Therapy
finance.yahoo.com - December 7 at 11:35 AM
How Much Did Sangamo Therapeutics(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years?How Much Did Sangamo Therapeutics'(NASDAQ:SGMO) Shareholders Earn From Share Price Movements Over The Last Three Years?
finance.yahoo.com - November 30 at 4:23 PM
Pfizer (PFE) Begins Phase III Study on Hemophilia CandidatePfizer (PFE) Begins Phase III Study on Hemophilia Candidate
finance.yahoo.com - November 24 at 2:48 PM
Sangamo Therapeutics, Inc. to Host Earnings CallSangamo Therapeutics, Inc. to Host Earnings Call
marketwatch.com - November 6 at 10:15 PM
Sangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call TranscriptSangamo Therapeutics, Inc. (SGMO) CEO Sandy Macrae on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 5 at 1:04 AM
Sangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call TranscriptSangamo Therapeutics Inc (SGMO) Q3 2020 Earnings Call Transcript
fool.com - November 4 at 11:39 PM
Sangamo Therapeutics EPS beats by $0.24, beats on revenueSangamo Therapeutics EPS beats by $0.24, beats on revenue
seekingalpha.com - November 4 at 8:03 PM
Sangamo Therapeutics Q3 2020 Earnings PreviewSangamo Therapeutics Q3 2020 Earnings Preview
seekingalpha.com - November 3 at 11:20 PM
Sangamo Therapeutics Announces Third Quarter 2020 Conference Call and WebcastSangamo Therapeutics Announces Third Quarter 2020 Conference Call and Webcast
finance.yahoo.com - October 28 at 7:01 PM
Will Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should KnowWill Sangamo Therapeutics (SGMO) Report Negative Q3 Earnings? What You Should Know
finance.yahoo.com - October 28 at 2:01 PM
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their HoldingsSangamo Therapeutics, Inc. (NASDAQ:SGMO) Insiders Increased Their Holdings
finance.yahoo.com - October 18 at 2:43 AM
This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.